FDA Nominee Overton Grilled on Mifepristone, Vaccines

The White House's pick to run the FDA spent nearly three hours on 24 September fielding pointed questions on two of the agency's most politically charged files — mifepristone and childhood vaccines — without fully satisfying either side of the Senate HELP Committee. Dr. Heidi Overton, a preventive-medicine physician and White House domestic-policy aide with no prior FDA experience, told senators mifepristone has “met the safety and efficacy standard according to the FDA review,” while repeatedly declining to say in her own words that she personally considers the drug safe.

A statutory answer, not a personal one

The exchange with Murray was the hearing's sharpest. Asked directly whether she believes mifepristone is safe, Overton returned to the agency's own findings rather than her own view: the drug, she said, “has met the safety and efficacy determinations of the FDA” and “has met the safety and efficacy standard according to the FDA review.” Multiple outlets covering the hearing noted the distinction — some headlines flattened it to Overton having “affirmed” the drug is safe, but the verbatim exchanges show she consistently routed the question back to FDA's institutional determination rather than offering a first-person assurance. That answer sits against Overton's own record: in February 2023, before joining the administration, she co-authored a piece describing medication abortion as “dangerous to women.” Murray raised that history directly in her questioning.

The stakes for the answer are concrete. FDA has an internal review of mifepristone's Risk Evaluation and Mitigation Strategy pending — a holdover from the Biden-era update that allowed the pill to be dispensed by mail — and the agency is currently a defendant in Louisiana litigation over mail-order access tied to that same REMS change. Overton told the committee that reviewing the status of that safety study would be “the most urgent thing” she would ask to be briefed on if confirmed, without previewing what she thinks the review should conclude.

Vaccines: agency-safe, not administration-wrong

On vaccines, Overton was more willing to speak in her own voice — up to a point. She told the committee MMR is the “best tool” the country has against measles and that “every vaccine on the U.S. market right now is safe and effective, according to the FDA.” But when senators cited President Trump's public comments describing the MMR vaccine as potentially “quite lethal,” Overton would not say he was wrong, a pattern several outlets highlighted as consistent with her broader posture of endorsing FDA's findings while avoiding direct conflict with the administration she serves. Cassidy, a physician himself, opened the hearing by raising his own concerns about Overton's role in the administration's vaccine-schedule executive order.

The rest of the docket

• Sen. Murray also pressed Overton on food-safety inspection failures at FDA, a separate line of committee criticism from the mifepristone questioning.
• Sen. Susan Collins (R-ME), an abortion-rights Republican whose vote could matter in committee, faced her own scrutiny over how she would vote given Overton's record.
• Senators also questioned Overton on flavored e-cigarettes, clinical trial oversight, orphan drug policy, and food-facility inspections — the broader portfolio a confirmed commissioner would inherit alongside CDER and CBER's drug and biologic review work.

No committee markup or floor vote has been scheduled as of this writing. Coverage of the hearing has flagged that the timeline for a vote — and its outcome — remains genuinely uncertain, with some reporting suggesting a resolution may not come until after November's midterm elections. Regulatory News will follow the nomination through markup and any floor vote.

Frequently asked questions

Who is Heidi Overton, and what is she nominated for?

President Trump's nominee for Commissioner of Food and Drugs. She is a board-certified preventive-medicine physician (MD, University of New Mexico; PhD in clinical investigation, Johns Hopkins Bloomberg School of Public Health) currently serving as Deputy Assistant to the President for Domestic Policy, after a prior role at the America First Policy Institute. She has no prior FDA post. At 37, she would be the youngest FDA commissioner in the agency's history if confirmed, succeeding Marty Makary, who resigned in May 2026.

What did she say about mifepristone?

Pressed by Sen. Patty Murray, Overton said mifepristone "has met the safety and efficacy determinations of the FDA" and "has met the safety and efficacy standard according to the FDA review" — statutory framing rather than a personal affirmation of safety. She declined to state in her own words that she considers the drug safe, and said the pending FDA review of the mifepristone REMS would be her top priority to get briefed on if confirmed.

What did she say about vaccines?

She called MMR the country's "best tool" against measles and said every FDA-authorized vaccine is "safe and effective." She declined to say President Trump was wrong when he described the MMR vaccine as potentially "quite lethal," and was questioned about her role in the administration's vaccine-schedule executive order.

What happens next in her confirmation?

This was Overton's first Senate HELP Committee hearing on the nomination, held 24 September 2026. No committee markup or floor vote date has been announced; reporting on the hearing indicates the timing and outcome of a committee vote remain uncertain.